Literature DB >> 2393286

Influence of lomefloxacin on the pharmacokinetics of theophylline.

M LeBel1, F Vallée, M St-Laurent.   

Abstract

The effect of multiple doses of lomefloxacin (400 mg twice a day) on the clearance of theophylline and the urinary excretion of its metabolites was investigated in 15 healthy male subjects. Concentrations of theophylline in plasma were measured by TDx (Abbott Diagnostics, Mississauga, Ontario, Canada). Urinary excretion of theophylline and its three major metabolites and lomefloxacin in plasma were assayed by high-performance liquid chromatography. Total theophylline clearance remained unchanged before lomefloxacin treatment and after lomefloxacin single- and multiple-dose treatments (58.02, 56.57, 54.07 ml/min, respectively). The urinary recovery of unchanged theophylline and its major metabolites stayed stable during the study. We conclude that lomefloxacin can be added to the list of fluoroquinolones that can be administered safely with theophylline.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2393286      PMCID: PMC171794          DOI: 10.1128/AAC.34.6.1254

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Safety of fleroxacin coadministered with theophylline to young and elderly volunteers.

Authors:  M Parent; M St-Laurent; M LeBel
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

2.  JANA: a new iterative polyexponential curve stripping program.

Authors:  A Dunne
Journal:  Comput Methods Programs Biomed       Date:  1985-08       Impact factor: 5.428

3.  Effect of lomefloxacin on theophylline pharmacokinetics.

Authors:  D E Nix; A Norman; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

4.  Interaction of quinolones with the theophylline metabolism in man: investigations with lomefloxacin and pipemidic acid.

Authors:  A H Staib; S Harder; U Fuhr; C Wack
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1989-06

Review 5.  Inhibition of drug metabolism by quinolone antibiotics.

Authors:  D J Edwards; S K Bowles; C K Svensson; M J Rybak
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

6.  New simplified microassay for the quantitation of theophylline and its major metabolites in serum by high-performance liquid chromatography.

Authors:  M B Kester; C L Saccar; M L Rocci; H C Mansmann
Journal:  J Chromatogr       Date:  1986-07-11

7.  Enoxacin--a potent inhibitor of theophylline metabolism.

Authors:  J Beckmann; W Elsässer; U Gundert-Remy; R Hertrampf
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

  7 in total
  7 in total

Review 1.  Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A N Wadworth; K L Goa
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

2.  Safety of fleroxacin coadministered with theophylline to young and elderly volunteers.

Authors:  M Parent; M St-Laurent; M LeBel
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

3.  Lack of interaction between lomefloxacin and caffeine in normal volunteers.

Authors:  D P Healy; J R Schoenle; J Stotka; R E Polk
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

Review 4.  Clinically significant pharmacokinetic interactions between dietary caffeine and medications.

Authors:  J A Carrillo; J Benitez
Journal:  Clin Pharmacokinet       Date:  2000-08       Impact factor: 6.447

Review 5.  Drug interactions with quinolone antibacterials.

Authors:  J R Brouwers
Journal:  Drug Saf       Date:  1992 Jul-Aug       Impact factor: 5.606

Review 6.  Lomefloxacin clinical pharmacokinetics.

Authors:  C D Freeman; D P Nicolau; P P Belliveau; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1993-07       Impact factor: 6.447

Review 7.  Pharmacokinetics of quinolones: newer aspects.

Authors:  J S Wolfson; D C Hooper
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.